AstraZeneca PLC (AZN)vsRepligen Corporation (RGEN)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
RGEN
Repligen Corporation
$113.11
-3.68%
HEALTHCARE · Cap: $6.38B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 7856% more annual revenue ($58.74B vs $738.26M). AZN leads profitability with a 17.4% profit margin vs 6.6%. AZN appears more attractively valued with a PEG of 1.54. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
RGEN
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+12.9%
Fair Value
$160.09
Current Price
$113.11
$46.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Earnings expanding 160.0% YoY
18.1% revenue growth
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
ROE of 2.4% — below average capital efficiency
6.6% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : RGEN
The strongest argument for RGEN centers on EPS Growth, Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : RGEN
The primary concerns for RGEN are Return on Equity, Profit Margin, PEG Ratio. A P/E of 131.5x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a value stock while RGEN is a growth play — different risk/reward profiles.
RGEN carries more volatility with a beta of 1.19 — expect wider price swings.
RGEN is growing revenue faster at 18.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 45/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Repligen Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?